Catalyst Pharmaceuticals (NASDAQ:CPRX) Acquisition: Earnings, Valuation, and Shareholder Scrutiny

Font: Financial Modeling Prep  • May 08, 2026

• Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to release its quarterly earnings amidst a pending acquisition by Angelini Pharma for $4.1 billion.
• The acquisition price of $31.50 per share is currently under investigation by Halper Sadeh LLC, scrutinizing the fairness for shareholders.
• Despite the acquisition, the biopharmaceutical company demonstrates robust financial health, characterized by a low debt-to-equity ratio and strong liquidity.

Catalyst Pharmaceuticals (NASDAQ:CPRX) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company is scheduled to release its quarterly earnings report on May 11, 2026. For this report, Wall Street analysts have set an earnings per share (EPS) estimate of $0.64 and a revenue estimate of around $149.52 million.

A major development impacts the company's usual earnings process. Catalyst Pharmaceuticals is set to be acquired by Italy's Angelini Pharma in a $4.1 billion deal, as highlighted by The Wall Street Journal. This marks Angelini's entry into the U.S. market. As a result of this pending acquisition, Catalyst Pharmaceuticals has cancelled its first-quarter 2026 conference call.

The acquisition is priced at $31.50 per share in cash. However, the investor rights law firm Halper Sadeh LLC is investigating the sale. The investigation questions whether Catalyst Pharmaceuticals and its board secured the best possible price for shareholders, as reported by Business Wire. The firm is also reviewing the fairness of the sales process.

Looking at its financial health, Catalyst Pharmaceuticals has a trailing price-to-earnings (P/E) ratio of 17.77. The P/E ratio compares a company's stock price to its earnings per share and is a common tool for valuation. The company also has a price-to-sales ratio of 6.47 and an earnings yield of 5.63%.

Catalyst Pharmaceuticals maintains a strong balance sheet. It has a very low debt-to-equity ratio of 0.003, indicating it uses very little debt to finance its assets. The company also shows strong liquidity with a current ratio of 6.08, which measures its ability to pay short-term obligations. A ratio above 1 is generally considered healthy.